Clinical trials: Allosensitization, open to volunteers
Type 1 Diabetes Mellitus
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
- Trial name
- NCT01999361
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Rodolfo Alejandro
Kidney Transplant, Kidney Transplant Failure
Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)
Kidney transplant is often the best treatment for people with kidney failure, but transplanted kidneys don't always last a lifetime.
- Conditions
- Kidney Transplant, Kidney Transplant Failure, Immunosuppresion
- Trial name
- NCT06802822
- Testing
- Prevention of Allosensitization
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- University of British Columbia